Extracellular Vesicles as New Players in Drug Delivery: A Focus on Red Blood Cells-Derived EVs

The article is divided into several sections, focusing on extracellular vesicles' (EVs) nature, features, commonly employed methodologies and strategies for their isolation/preparation, and their characterization/visualization. This work aims to give an overview of advances in EVs' extensi...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-01, Vol.15 (2), p.365
Main Authors: Biagiotti, Sara, Abbas, Faiza, Montanari, Mariele, Barattini, Chiara, Rossi, Luigia, Magnani, Mauro, Papa, Stefano, Canonico, Barbara
Format: Article
Language:English
Subjects:
Biosynthesis
cargo loading
Cells
Cerebrospinal fluid
Chemical properties
Communication
Drug delivery systems
Drugs
Erythrocytes
Extracellular vesicles
Health aspects
Innovations
Lipids
Materials
MicroRNAs
nanomedical drug delivery
Physiology
Proteins
red blood cell extracellular vesicles
Review
therapeutic applications
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The article is divided into several sections, focusing on extracellular vesicles' (EVs) nature, features, commonly employed methodologies and strategies for their isolation/preparation, and their characterization/visualization. This work aims to give an overview of advances in EVs' extensive nanomedical-drug delivery applications. Furthermore, considerations for EVs translation to clinical application are summarized here, before focusing the review on a special kind of extracellular vesicles, the ones derived from red blood cells (RBCEVs). Generally, employing EVs as drug carriers means managing entities with advantageous properties over synthetic vehicles or nanoparticles. Besides the fact that certain EVs also reveal intrinsic therapeutic characteristics, in regenerative medicine, EVs nanosize, lipidomic and proteomic profiles enable them to pass biologic barriers and display cell/tissue tropisms; indeed, EVs engineering can further optimize their organ targeting. In the second part of the review, we focus our attention on RBCEVs. First, we describe the biogenesis and composition of those naturally produced by red blood cells (RBCs) under physiological and pathological conditions. Afterwards, we discuss the current procedures to isolate and/or produce RBCEVs in the lab and to load a specific cargo for therapeutic exploitation. Finally, we disclose the most recent applications of RBCEVs at the in vitro and preclinical research level and their potential industrial exploitation. In conclusion, RBCEVs can be, in the near future, a very promising and versatile platform for several clinical applications and pharmaceutical exploitations.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15020365